About this trial
This study looks at how safe and effective a treatment called Peptide Receptor Radionuclide Therapy (PRRT) is for patients with specific types of gastroenteropancreatic neuroendocrine tumors (GEP-NET). These tumors are either Grade 1 or 2 and have spread to other areas like lymph nodes or the liver. The goal is to see if this treatment can help improve outcomes when given before and after surgery to remove the tumor.
This trial is identified by NCT04609592. It is a Phase 1 study, which means it is among the first to test the treatment for safety and effectiveness. The trial is regulated by the FDA and aims to enroll about 10 participants.
Who can join
Patients aged 18 and older can join this trial. It is open to both men and women who have metastatic gastroenteropancreatic NET that has spread to lymph nodes or the liver. Participants must be suitable for surgery aimed at complete removal of the tumor. Some patients may not be eligible if they have had certain treatments or if their tumors have spread to other areas like the brain or bones. The trial team will confirm eligibility before enrollment.
Condition
Gastroenteropancreatic Neuroendocrine Tumor
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive Lutathera, which includes 2 cycles of the treatment before surgery and possibly 2 more cycles afterward if needed. Participants will also undergo various imaging tests, including CT and MRI scans, to monitor their condition. There is no random assignment; everyone receives the same treatment.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
Stanford Cancer Institute Palo Alto
Stanford, California